Author:

  • All
  • --
  • ---
  • -2022
  • 2022-2
  • 2022-2-2-2
  • 2022-deltia-tipoy
  • 2022-deltia-tipoy-2-2
  • 2022-deltia-tipoy-2-2-2-2
  • 2023-deltia-typou
  • 2023-deltia-typou-2-2
  • 2024
  • 257-2
  • 257-2-2-2
  • 266-2
  • Announcements
  • Announcements 2025
  • Consolidated Financial Results
  • deltia-tipoy
  • deltia-tipoy-2-2
  • deltia-tipoy-2-2-2-2
  • Distribution of Divident
  • Events
  • FAQ
  • General Meetings and Corporate Actions
  • Insiders Transactions Disclosures
  • Invitations
  • invitations-2
  • Presentations
  • Press Kits
  • Press Releases
  • Regulated Information
  • Results 2024
  • Share Capital Increase
  • Uncategorized

Paiania, 6 December 2023 - Marking a remarkable year since its successful Share Capital Increase, Lavipharm, the sole Greek pharmaceutical company listed on the Athens Stock Exchange, proudly commenced today’s trading session. At this special event held at the Athens Exchange, Telemaque Lavidas, Executive Board...

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...

Paiania, 8 November 2023 - Lavipharm S.A. announces key financial figures for the nine-month period of 2023 and business developments during third quarter: Lavipharm Key Financial Figures Q3 2023  ...

Peania, 21 September 2023– Lavipharm (LAVI) reports a significant increase in consolidated sales and EBITDA during the First Half of 2023. The impressive results exceed sales forecasts, as disclosed in the prospectus of the recent share capital increase, for a second consecutive year. Specifically, consolidated Sales,...

Peania, 19 September 2023 - Lavipharm joins voices with MDA Hellas, that organizes a unique concert featuring the leading singer-songwriter Nikos Portokaloglou and the renowned singer Rena Morfi. The concert will take place tomorrow, 20 September (21.00) at the Veakio Municipal Theatre of Piraeus. The concert...

Παιανία, 7 Σεπτεμβρίου 2023 - Η Lavipharm, διαχρονικός αρωγός του MDA Ελλάς, Σωματείο Φροντίδας Ατόμων με Νευρομυϊκές Παθήσεις, συμμετέχει ως χορηγός στη διαδικτυακή εκδήλωση που θα πραγματοποιηθεί σήμερα,  7 Σεπτεμβρίου 2023, στις 17:00, στο πλαίσιο της 10ης Παγκόσμιας Ημέρας Ευαισθητοποίησης για τη Μυϊκή Δυστροφία Duchenne...

Παιανία, 14 Ιουλίου 2023 – Η ανώνυμη εταιρεία με την επωνυμία «ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ, ΧΗΜΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ LAVIPHARM A.E.» και τον διακριτικό τίτλο «LAVIPHARM AE» (εφεξής, η «Εταιρεία»), γνωστοποιεί στο επενδυτικό κοινό σύμφωνα με τις διατάξεις του Ν. 3556/2007 (άρθρο 3 παρ....

Peania, 6 July 2023 – Lavipharm’s (LAVI) Annual Shareholders Meeting was held today at the corporate headquarters in Peania. The meeting was completed with the necessary quorum, as 33 shareholders participated representing a percentage 70.78%. The General Assembly began its proceedings with the welcome speech of...